US prostate cancer market diagnostics and therapeutics are forecast to augment at a CAGR of 10.4% during the forecast period. The major factors for the growth of the market include the high prevalence of prostate cancer in the country. As per the World Health Organization, in US prostate cancer is the most prevalent cancer among men. Around 212,000 new cases of prostate cancer have been registered in 2018 in the country which is around 18.5% of the overall cancer cases. Moreover, it is the sixth-highest reason for mortality in the country due to cancer. In 2018, around 29,000 mortalities were registered in the country. According to the American Cancer Society, nearly $12 billion in treatment is spent every year for prostate cancer treatment. In addition, the adoption of innovative technologies for the diagnosis of prostate cancer such as biomarkers and the adoption of personalized medicine for treatment is expected to fuel the market.